PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial

Liselore Loverix, Ignace Vergote, Pieter Busschaert, Adriaan Vanderstichele, Tom Venken, Bram Boeckx, Philipp Harter, Hilde Brems, Els Van Nieuwenhuysen, Sandro Pignata, Thaïs Baert, Antonio González-Martı́n, Sileny Han, Christian Marth, Patrick Neven, Nicoletta Colombo, Patrick Berteloot, Johanna Mäenpää, Siel Olbrecht, Tina Laga, Erwin Sablon, Isabelle Ray‐Coquard, Éric Pujade-Lauraine, Diether Lambrechts, Toon Van Gorp